Obstetrics and gynaecology · Hard
This case is fictional and exists for study. It describes no real patient.
54 years · female
A 54-year-old woman presents to the gynaecology clinic with a 3-week history of light, painless vaginal bleeding. She underwent menopause two years ago. Her past medical history is significant for stage II invasive ductal carcinoma of the breast, diagnosed 3 years ago, for which she underwent breast-conserving surgery and radiotherapy, and is currently taking adjuvant tamoxifen daily. She takes no other medications. On abdominal examination, there is no tenderness or palpable mass. Speculum examination confirms a small amount of dark blood originating from the external cervical os, with a normal-appearing cervix. Bimanual examination reveals a normal-sized, non-tender, mobile uterus with no adnexal masses.
Vital signs
- HR
- 78 bpm
- BP
- 128/82 mmHg
- RR
- 14/min
- Temp
- 36.7 °C
- SpO₂
- 99%
Examination findings
- Dark blood emerging from the external cervical os
- Normal-appearing cervix on speculum examination
- Normal-sized, non-tender uterus without adnexal pathology
Investigations
| Haemoglobin | 12.1 g/dL | reference: 12.0-15.5 |
| Platelets | 240 10^9/L | reference: 150-400 |
| Serum hCG | <5 IU/L | reference: <5 |
Question 1 of 3
Which of the following is the most appropriate initial investigation to evaluate the endometrial cavity in this patient?
In patients taking tamoxifen who present with postmenopausal bleeding (PMB), direct evaluation via outpatient hysteroscopy and endometrial biopsy (or Pipelle biopsy alongside TVUS) is recommended. Transvaginal ultrasound (TVUS) in tamoxifen users often overestimates endometrial thickness due to subepithelial stromal hypertrophy and cystic reorganisation. Hysteroscopy allows direct visualization of focal lesions like polyps and targeted tissue sampling. Serum CA-125 (Option B) is primarily used in ovarian cancer investigations, not PMB. MRI pelvis (Option C) is used for staging established endometrial carcinoma rather than primary evaluation. Delaying evaluation for 6 weeks (Option A) is inappropriate given the red-flag symptom of postmenopausal bleeding.
Teaching point: Patients on tamoxifen presenting with postmenopausal bleeding require direct endometrial evaluation, such as hysteroscopy and tissue biopsy, due to ultrasound limitations and malignancy risk.
Question 2 of 3
If histological assessment reveals atypical endometrial hyperplasia, which mechanism is primarily responsible for this condition in this patient?
Tamoxifen is a Selective Oestrogen Receptor Modulator (SERM). While it acts as an oestrogen receptor antagonist in breast tissue, it acts as a partial oestrogen receptor agonist in the endometrium. Unopposed oestrogenic stimulation leads to endometrial proliferation, predisposing to endometrial polyps, hyperplasia, and adenocarcinoma. Option D is incorrect because tamoxifen acts on oestrogen receptors, not progesterone receptors. Option A describes peripheral aromatisation in obese postmenopausal women, which can cause hyperplasia but is not the primary drug-induced driver here. Option B causes thin, fragile endometrium (atrophic endometritis), not hyperplasia.
Teaching point: Tamoxifen acts as an oestrogen receptor agonist in endometrial tissue, increasing the risk of endometrial hyperplasia and malignancy.
Question 3 of 3
Histological analysis confirms atypical endometrial hyperplasia (endometrial intraepithelial neoplasia). The patient remains fit for surgery. What is the most appropriate definitive management step?
Atypical endometrial hyperplasia carries a high risk (up to 40%) of coexisting invasive endometrial adenocarcinoma or progression to cancer. Total hysterectomy with bilateral salpingo-oophorectomy (TH+BSO) is the definitive standard management for postmenopausal women who are surgical candidates. LNG-IUS (Option D) and oral progestins like megestrol (Option C) are conservative options reserved for women wishing to preserve fertility or those medically unfit for surgery. Cessation of tamoxifen alone (Option B) is insufficient to manage established atypical hyperplasia.
Teaching point: Total hysterectomy with bilateral salpingo-oophorectomy is the definitive treatment for atypical endometrial hyperplasia in postmenopausal women.
Key learning points
- Postmenopausal bleeding in women taking tamoxifen requires prompt structural and histological evaluation of the endometrium.
- Tamoxifen exhibits tissue-specific SERM activity: antagonist in breast tissue but agonist in the endometrium.
- Atypical endometrial hyperplasia carries a substantial risk of concurrent or future malignancy and is definitively managed with total hysterectomy and bilateral salpingo-oophorectomy in eligible patients.
This is one of 158 free cases
AskPreceptor is a study tool for medical students: answer first, then see the reasoning — including why each wrong option is wrong. Free, no sign-up required.